Indoco Remedies Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹476Cr
- +22.1% YoY
- +7% QoQ
- Net profit
- −₹24Cr
- Q4 FY25: −₹41 Cr
- Margin
- 10%
- +10.2 pp YoY
- +3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Indoco Remedies Q4 FY26 key numbers
- Revenue
- Warren Remedies (India OTC): Business grown from INR 90-94 crore to INR 120-130 crore; expecting further growth with key brands and new product launches.
As stated in Indoco Remedies's Q4 FY26 earnings call transcript · published 18 Aug 2026. Reported figures, not investment advice.
The short version
India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well. Europe business and base contract manufacturing expected to grow with better margins due to completed MMP scale-ups.
From Indoco Remedies's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well.
- Regulated Markets (Europe & US): Continued growth anticipated with better margins, especially from contract manufacturing; expansion into liquid oral products planned for FY '27-'28.
- Emerging Markets: High confidence for growth in next 2-3 years driven by strong portfolio and active field force in Africa regions.
- Warren Remedies (India OTC): Business grown from INR 90-94 crore to INR 120-130 crore; expecting further growth with key brands and new product launches.
2 more points from Indoco Remedies's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Indoco Remedies said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major CAPEX is planned for the next 2 years as per Pramod Ghorpade's statement.
- Current focus is on tight control of CAPEX and reducing operating expenses.
- API plant has ongoing validations and capital expenditure already done, but no new significant investments are planned.
2 more points from Indoco Remedies's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indoco Remedies said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Indoco Remedies's call on order book
Create a free account to keep reading this call
Indoco Remedies — Quarterly revenue & net profit
Indoco Remedies Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 476 | 390 | +22.1% | 445 | +7% |
| Operating profit (EBITDA) | 50 | -1 | — | 32 | +56.3% |
| Operating margin | 10% | -0.2% | +10.2 pp | 7% | +3 pp |
| Profit before tax | -25 | -46 | — | -31 | — |
| Net profit (PAT) | -24 | -41 | — | -29 | — |
| EPS (₹) | -2.34 | -4.38 | — | -3.23 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹520 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indoco Remedies's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Indoco Remedies and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indoco Remedies Q4 FY26 results?
India Business: Expected to grow in line with IPM; focus on new product launches (e.g., Drotitec M, Vepazil, Cyclopam AC suspension) contributing around INR 20 crore annually, with new launches performing well. Europe business and base contract manufacturing expected to grow with better margins due to completed MMP scale-ups.
What is Indoco Remedies share price analysis?
Indoco Remedies currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,026 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indoco Remedies planning capital expenditure?
No major CAPEX is planned for the next 2 years as per Pramod Ghorpade's statement.
Keep Indoco Remedies on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
